Analysis of Circulating Exosomes in Melanoma Patients
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- Quantification of circulating exosomes
研究概览
简要总结
The hypothesis is that PD-L1[Programmed Death-Ligand 1] labeling in exosomes could be a biomarker of disease progression in melanoma. The rate of circulating exosomes, their size and the exosomal expression of PD-L1 could be correlated with the stage of the disease, the response to treatment and/or the prognosis of patients. In this study, blood samples (EDTA tubes taken as part of routine care at Besançon University Hospital) and associated clinical data are reused.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Melanoma patients admitted in Besançon University Hospital
- •exigible for immunotherapy such as anti PD-L1/PD-1
- •Age ≥18 years
- •Affiliation to a social security system,
排除标准
- •Minor patients
- •Patients who have expressed their opposition to the reuse of their data and biological samples
结局指标
主要结局
Quantification of circulating exosomes
时间窗: Day 1
Dosage of proteic biomarkers in circulating exosomes, plasma and tumor tissues. Blood samples were taken in standard care, before initiation of immunotherapy and then during disease follow-up until progression and tumor evaluation
次要结局
- Other proteins detection(Day 1)
- PDL1 marking(Day 1)
- Determine whether the initial exosome concentration (at T0) is associated with a response to treatment.(Day 1)
